Pq Bypass News 2

PQ Bypass Announces CE Mark for DETOUR Percutaneous Bypass

Seroba’s investee company, PQ Bypass, today announced CE (Conformité Européenne) Mark approval for a trio of proprietary devices: TORUS™ Stent Graft System, PQ Snare, and PQ Crossing Device, which enables physicians to perform a fully percutaneous femoral-popliteal bypass in patients with TransAtlantic InterSociety (TASC) II C and D lesions in the superficial femoral artery due to peripheral artery disease (PAD).

More than 200 million people worldwide are affected by PAD, which is a potentially life-threatening condition.1 In complex PAD, arteries in the leg become blocked by extremely long segments of plaque, restricting blood flow to the lower extremities. This can lead to pain, loss of mobility and amputation. Historically, extremely long blockages were treated by open bypass surgery, however experts now consider an endovascular-first approach. While standard endovascular approaches decrease procedure morbidity associated with surgery, they have not yet demonstrated the durability of open bypass surgery.2 The DETOUR procedure, pioneered by PQ Bypass, is designed to match or exceed the durable patency associated with open surgical bypass, but achieve those results with a minimally invasive endovascular procedure that allows rapid return to full function.

The TORUS™ Stent Graft System is an expanded polytetrafluoroethylene (ePTFE) covered self-expanding nitinol stent intended to improve blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery de novo and restenotic TASC II C and D lesions. The PQ Snare and PQ Crossing Devices are intended for the retrieval and manipulation of atraumatic foreign bodies in the distal peripheral vasculature and to support the placement and positioning of guidewires in the peripheral vasculature, respectively.

“There is a great unmet need for a durable percutaneous option for these patients with extremely long blockages in the legs due to PAD,” said Dr. Sean Lyden, chairman of the Robert and Suzanne Tomsich Department of Vascular Surgery at Cleveland Clinic’s Sydell and Arnold Miller Family Heart & Vascular Institute. “While other percutaneous approaches have been attempted, long-term success and patency have been difficult to achieve, resulting in limited options for these patients.”

The CE Mark approval was based on data collected in DETOUR I, a prospective, multi-center, core-lab reviewed single-arm trial designed to evaluate the safety and efficacy of the PQ DETOUR procedure in patients with TASC II C and D total occlusions in the femoral-popliteal anatomy. The 6-month results from DETOUR I, which were presented in January at the Leipzig Interventional Course (LINC 2017), met both primary safety and effectiveness endpoints.

“The PQ DETOUR procedure is a truly new and innovative approach to treating patients with extremely long SFA lesions,” said Dainis Krievins, MD, PhD, professor of vascular surgery, University of Latvia, Director, Institute of Research of Pauls Stradins Clinical University Hospital, Riga, Latvia, and investigator in the DETOUR I study. “The initial safety and effectiveness of the DETOUR procedure, as shown in the DETOUR I trial, is very encouraging and the results clearly demonstrate the potential for this to become a key addition to the treatment armamentarium for patients with complex PAD.”

The PQ DETOUR procedure is a fully-percutaneous femoral-popliteal bypass procedure. Using fluoroscopic guidance, a series of proprietary TORUS™ Stent Grafts are deployed from the popliteal artery into the femoral vein, and from the femoral vein into the superficial femoral artery in a continuous, overlapping fashion through two independent anastomoses. The final result is a large lumen, endograft bypass that delivers unobstructed, pulsatile flow from the SFA ostium to the popliteal artery, restoring blood flow to the lower extremities.

“With an increased focus on value-based and patient-centered medicine, surgical advancements that minimize trauma to patients, reduce length of hospital stay and recovery times are critical global needs,” said Peter Wehrly, president and CEO of PQ Bypass. “CE Mark is an important milestone for PQ Bypass and we look forward to continuing our clinical studies, including an upcoming IDE study, with an eye toward FDA approval. Data presented at LINC 2017 demonstrated that the DETOUR procedure has clear potential as a viable change in how extremely long SFA occlusive disease is treated in the future.”

For further information, please contact Vicky La Touche-price in Seroba on +3531 6334028.

About PQ Bypass

PQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally-invasive endovascular solutions.

PQ Bypass is operated by recognized leaders in the medical device industry. Our executive team members have held senior leadership positions at companies including Medtronic, Abbott, Johnson & Johnson, Covidien, and Stryker and also have extensive experience developing medical devices for startups such as Evalve, AccessClosure, Altura, Avinger, and DVI.

The underlying technology and technique used in the percutaneous PQ DETOUR procedure were co-developed by two world-renowned cardiologists and innovators, Dr. James Joye and Dr. Richard Heuser, who are recognized experts in PAD.

The PQ Bypass technology platform is not available for sale in the US.  For more information, please visit www.pqbypass.com

1 Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE,Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–1340. doi: 10.1016/S0140-6736(13)61249-0
2 Alber M, Romiti M, Brochado-Neto FC, et al. Meta-analysis of alternate autologous veins bypass grafts to infrapopliteal arteries. J Vasc Surg. 2005;42:449-55.

Recent Articles

STORM Therapeutics Logo

FutureNeuro partners with STORM Therapeutics to explore the role of RNA epigenetics in epilepsy.

Dublin, Ireland.  9 September 2020.  FutureNeuro has announced that it has entered into partnership with Seroba’s portfolio company, STORM Therapeutics, […]

Read More
Pq Bypass

PQ Bypass Receives FDA “Breakthrough Device Designation” for the World’s First Fully Percutaneous Femoral-Popliteal Bypass Device.

MILPITAS, Calif. – September 2, 2020 – PQ Bypass Inc, a medical device pioneer bringing new advancements to the treatment […]

Read More
Susan Trent Photo

Atlantic Therapeutics appoints Susan Trent as new CEO, based in the United States.

Galway, Ireland.   Seroba’s portfolio company, Atlantic Therapeutics, a Galway-based MedTech and Femtech innovator, announces a transition in leadership to fulfill […]

Read More
Cancer Killers

Fusion Pharmaceuticals Announces Pricing of Initial Public Offering.

HAMILTON, ONTARIO and Boston. 25 June 2020.  Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19

Scroll to Top